Neil Gunn
Chief Executive Officer chez GENETIC SIGNATURES LIMITED
Fortune : - $ au 31/03/2024
Profil
Neil Gunn is currently the Chief Executive Officer & Director at Genetic Signatures Ltd., the Independent Director at NeoGenomics, Inc., the Independent Director at Rarecells USA, Inc., the Independent Director at Alveo Technologies, Inc., and the Director at Rarecells Diagnostics SAS.
Previously, he served as the Chief Executive Officer & Director at IDbyDNA, Inc., the Vice President at Roche Molecular Systems, Inc., and the Head-Global Business at Roche Sequencing Solutions, Inc. Dr. Gunn obtained his undergraduate degree from Nottingham Trent University and his graduate and doctorate degrees from the University of Portsmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENETIC SIGNATURES LTD.
-.--% | 30/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Neil Gunn
| Sociétés | Poste | Début |
|---|---|---|
| GENETIC SIGNATURES LIMITED | Chief Executive Officer | 30/04/2024 |
| NEOGENOMICS, INC. | Director/Board Member | 26/06/2023 |
Alveo Technologies, Inc.
 Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | Director/Board Member | 13/05/2021 |
Rarecells USA, Inc.
 Rarecells USA, Inc. Packaged SoftwareTechnology Services Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011. | Director/Board Member | 06/09/2022 |
Rarecells Diagnostics SAS
 Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The private company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Director/Board Member | - |
Anciens postes connus de Neil Gunn
| Sociétés | Poste | Fin |
|---|---|---|
IDbyDNA, Inc.
 IDbyDNA, Inc. BiotechnologyHealth Technology IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA. | Chief Executive Officer | - |
Roche Molecular Systems, Inc.
 Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Corporate Officer/Principal | - |
Roche Sequencing Solutions, Inc.
 Roche Sequencing Solutions, Inc. Medical/Nursing ServicesHealth Services Roche Sequencing Solutions, Inc. engages in providing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. The firm's solutions include NGS Oncology Assays, sample collection, nucleic acid extraction and library preparation. The company is headquartered in Pleasanton, CA. | President | - |
Formation de Neil Gunn
| Nottingham Trent University | Undergraduate Degree |
| University of Portsmouth | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NEOGENOMICS, INC. | Health Services |
| GENETIC SIGNATURES LIMITED | Commercial Services |
| Entreprise privées | 6 |
|---|---|
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA. | Health Services |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011. | Technology Services |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA. | Health Technology |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | Health Technology |
Roche Sequencing Solutions, Inc.
Roche Sequencing Solutions, Inc. Medical/Nursing ServicesHealth Services Roche Sequencing Solutions, Inc. engages in providing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. The firm's solutions include NGS Oncology Assays, sample collection, nucleic acid extraction and library preparation. The company is headquartered in Pleasanton, CA. | Health Services |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The private company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Technology Services |
